Market news

Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: Wells Fargo Healthcare ConferenceTuesday, September 8, 2026, at 3:00 p.m. ETH.C. Wainwright Healthcare ConferenceMonday, September 14, 2026, at 1:

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

Accomplished human resources executive brings more than 20 years of leadership experience building high-performing organizations through clinical development and commercialization Nurix Therapeutics Chief Human Resources Officer Wes Burwell, Nurix Therapeutics Chief Human Resources Officer BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cance

Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after a

Nurix Therapeutics (NRIX) has an average rating of buy and mean price target of $33.50, according to

Nurix Therapeutics (NasdaqGM:NRIX) announced a $10 million milestone payment tied to the first in human trial of an oral STAT6 degrader in its collaboration with Sanofi. The company also reported enrollment of the first patient in a pivotal global Phase 3 trial of bexobrutideg for relapsed or refractory chronic lymphocytic leukemia in partnership with Roche. Both programs advance Nurix's clinical pipeline in targeted protein degradation and expand its work with large pharmaceutical...

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well as potential royalties, and retains a U.S. co-development and co-promotion option BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharma

Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitorBRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating bexobrutideg, a potential best-in-class targeted protein degrader of Bruton’s tyrosine kinase (BTK),

Nurix AI, an enterprise AI company building autonomous AI agents for complex business workflows, today announced that it has rebranded as NuPlay AI, reflecting its evolution from a conversational AI company into a platform for building and operating self-improving agentic systems across the enterprise.

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Nurix Therapeutics (NRIX) has an average rating of buy and mean price target of $32.50, according to

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Summary

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes comprehensive clinical development plan in malignant hematology and enables expansion of bexobrutideg into chronic spontaneous urticaria (CSU) and multiple sclerosis (MS) Presented clinical data update at the European Hematology Association (EHA) supporting bexobrutideg's potential as

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -10.96% and -36.76%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?